Company intelligence / Profile preview

Courage Therapeutics

Newton, Massachusetts, United Statescouragetx.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Courage has developed MC4R peptide agonists that demonstrate synergy with GLP1RA drugs for obesity treatment, showing improved efficacy without increased side effects. Their candidates have higher potency and selectivity than setmelanotide with no MC1R activity. They also have first-in-class MC3R peptide agonists with demonstrated activity in CNS to increase feeding behavior in mouse models[8][9].

Therapeutic areas: PsychiatryMetabolic DisordersEndocrinologyGeriatricsWomen's HealthOncology
Modalities: PeptidesSmall molecules
Industry: Biotech

Drug pipeline

3 assets

Courage Therapeutics-MC4R-General Obesity

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Seeking strategic partners with GLP1RA therapeutic programs

Beyond the preview

Go deeper on Courage Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Courage Therapeutics.

Explore the full profile